Calithera Biosciences (CALA) Upgraded to Buy at Citigroup

Citigroup upgraded shares of Calithera Biosciences (NASDAQ:CALA) from a neutral rating to a buy rating in a report released on Friday. They currently have $14.00 price objective on the biotechnology company’s stock, up from their previous price objective of $6.95.

Other research analysts also recently issued reports about the company. Zacks Investment Research downgraded Calithera Biosciences from a buy rating to a hold rating in a report on Tuesday, January 2nd. ValuEngine downgraded Calithera Biosciences from a sell rating to a strong sell rating in a report on Saturday, February 3rd. Finally, BidaskClub downgraded Calithera Biosciences from a sell rating to a strong sell rating in a report on Thursday, January 18th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus target price of $16.67.

Shares of Calithera Biosciences (CALA) traded up $1.15 on Friday, reaching $8.10. The company’s stock had a trading volume of 3,522,712 shares, compared to its average volume of 516,387. The firm has a market cap of $246.56, a P/E ratio of -8.18 and a beta of 2.57. Calithera Biosciences has a 52-week low of $6.57 and a 52-week high of $20.05.

A number of hedge funds have recently bought and sold shares of CALA. Cubist Systematic Strategies LLC increased its holdings in Calithera Biosciences by 10.9% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 14,972 shares of the biotechnology company’s stock worth $222,000 after purchasing an additional 1,472 shares in the last quarter. Raymond James Financial Services Advisors Inc. increased its holdings in Calithera Biosciences by 68.1% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 17,000 shares of the biotechnology company’s stock worth $252,000 after purchasing an additional 6,885 shares in the last quarter. Wells Fargo & Company MN increased its holdings in Calithera Biosciences by 25.8% during the 3rd quarter. Wells Fargo & Company MN now owns 33,742 shares of the biotechnology company’s stock worth $531,000 after purchasing an additional 6,910 shares in the last quarter. Teachers Retirement System of The State of Kentucky increased its holdings in Calithera Biosciences by 49.2% during the 2nd quarter. Teachers Retirement System of The State of Kentucky now owns 27,600 shares of the biotechnology company’s stock worth $410,000 after purchasing an additional 9,100 shares in the last quarter. Finally, Trexquant Investment LP bought a new stake in Calithera Biosciences during the 3rd quarter worth approximately $168,000. 72.89% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/17/calithera-biosciences-cala-upgraded-to-buy-at-citigroup.html.

Calithera Biosciences Company Profile

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Analyst Recommendations for Calithera Biosciences (NASDAQ:CALA)

Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply